Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Free Cash Flow of -$14.7 million for Q1 2026, up 66.35% year-over-year from -$8.9 million in Q1 2025, and up 14.52% quarter-over-quarter from -$17.2 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Free Cash Flow data on file, last reported at -$14.7 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$14.7 million, up 66.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$38.8 million (up 76.97% YoY), and the FY2025 annual result was -$67.9 million, up 62.27% from the prior year.
- Free Cash Flow advanced to -$14.7 million in Q1 2026 per LXRX's latest filing, from -$17.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $17.0 million in Q2 2025 and troughed at -$55.1 million in Q1 2024.
- A 5-year average of -$30.3 million and a median of -$24.4 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 121.56% in 2023, then soared 134.83% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$22.8 million in 2022, then sank by 121.56% to -$50.5 million in 2023, then surged by 56.55% to -$22.0 million in 2024, then increased by 21.54% to -$17.2 million in 2025, then increased by 14.52% to -$14.7 million in 2026.
- Business Quant data shows LXRX's Free Cash Flow at -$14.7 million in Q1 2026, -$17.2 million in Q4 2025, and -$23.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -14.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.73 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Dec 31, 2024 | -21.97 Mn |
| Dec 31, 2024 | -21.97 Mn |
| Sep 30, 2024 | -53.93 Mn |
| Sep 30, 2024 | -53.93 Mn |
| Jun 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.79 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Dec 31, 2023 | -50.55 Mn |
| Dec 31, 2023 | -50.55 Mn |